Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RPT1-CNS
- Development stage
- Preclinical
- Lead developer
- Remedy Plan Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RPT1-CNS is a preclinical-stage small molecule hyperbolic inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) developed by Remedy Plan Therapeutics. It is specifically designed for the treatment of glioma. Unlike traditional complete NAMPT inhibitors that cause severe on-target toxicities by shutting down NAD+ synthesis entirely, RPT1-CNS utilizes a unique hyperbolic inhibition mechanism. This approach partially decreases NAMPT activity to a level that selectively starves energy-demanding cancer cells of NAD+ while preserving sufficient metabolic function in healthy brain and central nervous system tissues.
02
Targets
NAMPT
Beyond the preview
Go deeper on RPT1-CNS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RPT1-CNS.